The present invention generally relates to biocompatible devices suitable for increasing cellular HIF-1 ± protein levels. In particular, the present invention relates to an implant comprising a biocompatible support loaded with at least one pharmaceutical agent capable of increasing cellular HIF-1 ± protein levels to promote vascularization at or near the implant site. Vascularization of the implanted support results in enhanced survival of cells optionally incorporated within the support. Methods for treating a disease or injury via implanting the support of the present invention are also provided.
